Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracersKoller, M., Qiu, S-Q., Linssen, M. D., Jansen, L., Kelder, W., de Vries, J., Kruithof, I., Zhang, G-J., Robinson, D. J., Nagengast, W. B., Jorritsma-Smit, A., van der Vegt, B. & van Dam, G. M., 18-Sep-2018, In : Nature Communications. 9, 1, 11 p., 3739.
Research output: Contribution to journal › Article › Academic › peer-review
During the last decade, the emerging field of molecular fluorescence imaging has led to the development of tumor-specific fluorescent tracers and an increase in early-phase clinical trials without having consensus on a standard methodology for evaluating an optical tracer. By combining multiple complementary state-of-the-art clinical optical imaging techniques, we propose a novel analytical framework for the clinical translation and evaluation of tumor-targeted fluorescent tracers for molecular fluorescence imaging which can be used for a range of tumor types and with different optical tracers. Here we report the implementation of this analytical framework and demonstrate the tumor-specific targeting of escalating doses of the near-infrared fluorescent tracer bevacizumab-800CW on a macroscopic and microscopic level. We subsequently demonstrate an 88% increase in the intraoperative detection rate of tumor-involved margins in primary breast cancer patients, indicating the clinical feasibility and support of future studies to evaluate the definitive clinical impact of fluorescence-guided surgery.
|Number of pages||11|
|Publication status||Published - 18-Sep-2018|
- BREAST-CONSERVING SURGERY, STAGE-I, CANCER, MARGINS, IRRADIATION, THERAPY, SAFETY, 1ST